Domainex Ltd Launches Discovery STAR Award to Support Early Academic Drug Discovery
Published: Jan 22, 2013
Domainex’s STAR Award scheme will provide successful applicants with virtual hit screening using Domainex’s LeadBuilder platform and/or drug discovery consultancy services. The aim will be to bridge a current ‘funding gap’ for these activities, thereby allowing projects to progress to an inflection point that is suitable for larger external grant-funding schemes such as the TSB/MRC Biomedical Catalyst Fund, The Wellcome Trust’s SDDI scheme, European Union FP7, and MRC DPFS.
Translational research is the conversion of early-stage discoveries into new health products. Domainex is a leader in the support of academic translational research and has secured funding with numerous groups at the forefront of drug target research. Once funding is in place, and in full collaboration with the academic partner, Domainex has then deployed its own capabilities in medicinal and computational chemistry, biochemistry and DMPK testing to progress hit compounds through to the identification of clinical candidate drugs.
Eddy Littler, Chief Executive Officer of Domainex, said: “Domainex has successfully supported numerous academic groups across Europe and UK to apply for drug discovery funding from a range of sources – these include The Institute of Cancer Research; St. George’s, University of London; and the University of Manchester. However, small-molecule hits are typically required before funding can be secured, and the application process can be challenging for those without a commercial background. Domainex’s Discovery STAR Award will enable this gap to be filled for the selected recipients.”
Domainex is a drug discovery company that provides services, including computational and medicinal chemistry, gene cloning and expression, to pharmaceutical and biotechnology companies and to academic research groups. It also offers a unique proprietary technology known as Combinatorial Domain Hunting which is a patented method for expressing difficult protein targets. LeadBuilder is the proprietary lead generation platform that has been developed by Domainex to provide unusually rapid and cost-effective access to high-quality hits. As such, it is particularly well-suited to the needs of groups engaged in translational research, and emerging biotechnology and pharmaceutical companies. Domainex is also developing its own pipeline of pre-clinical drug candidates.
Domainex is based on the Cambridge Science Park, England and has offices in the London Bioscience Innovation Centre.
About Domainex’s Discovery STAR award
Domainex has launched its Discovery STAR award to support the early stages of drug discovery for a chosen number of applicants to the scheme. At Domainex’s discretion, selected applicants will then be provided with drug discovery advice and selected services free of charge in order to prepare applicants for funding applications to schemes such as the Wellcome Trust SDDI, Technology Strategy Board, Biocatalyst Fund or MRC DPFS.
Domainex plans to operate this scheme every 6 months. The deadline for this round is 15th March 2013.
Head of Business Development
Tel +44 (0)7775 437107